ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020
September 08 2020 - 1:00AM
Geneva, Switzerland and Boston, MA – September 8,
2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage
biopharmaceutical company developing and commercializing novel
therapies to improve women’s reproductive health, today announced
that CEO Ernest Loumaye will present an update on the Company and
its pipeline at the H.C Wainwright 22nd Annual Global Investment
Virtual Conference taking place September 14-16, 2020.
Mr. Loumaye’s presentation will take place on
Wednesday September 16 at 12:00 p.m. Eastern Time (ET). A
live presentation link will be available under “Events Calendar” in
the investors section of ObsEva’s website at www.ObsEva.com
About ObsEva
ObsEva is a biopharmaceutical company developing
and commercializing novel therapies to improve women’s reproductive
health and pregnancy. Through strategic in-licensing and
disciplined drug development, ObsEva has established a late-stage
clinical pipeline with development programs focused on treating
endometriosis, uterine fibroids, preterm labor, and improving ET
outcomes following IVF. ObsEva is listed on the Nasdaq Global
Select Market and is trading under the ticker symbol "OBSV" and on
the SIX Swiss Exchange where it is trading under the ticker symbol
“OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office contactShauna
DillonShauna.dillon@obseva.ch+41 22 552 1550
Investor ContactMario CorsoVice President,
Investor Relationsmario.corso@obseva.com
+1 857 972 9347 Office+1 781 366 5726 Mobile
ObsEva (NASDAQ:OBSV)
Historical Stock Chart
From Mar 2024 to Apr 2024
ObsEva (NASDAQ:OBSV)
Historical Stock Chart
From Apr 2023 to Apr 2024